source
- FDA rejects Capricor's Duchenne cell therapy again, citing major trial flawsCapricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
- Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competitionRevolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…